BIRMINGHAM, Ala. & CLEMMONS, N.C.–(BUSINESS WIRE)–Advancing Sight Network and Miracles In Sight today jointly announced the merger of the two organizations, which will begin operating as one on January 1, 2026. Globally, at least 253 million people l…
Author: Business Wire
DefEYE, Inc. Announces Investment from ExSight Ventures
NEW YORK–(BUSINESS WIRE)–ExSight Ventures, a leading venture capital firm focused on transformational eye care innovations, today announced its investment in DefEYE, Inc., a rapidly growing ocular company developing decellularized placental-based tis…
PRISM Vision Group Marks Milestone in National Expansion with Spokane Eye Clinic Affiliation
NEW PROVIDENCE, N.J.–(BUSINESS WIRE)–PRISM Vision Group closed a transaction with Spokane Eye Clinic, through which Spokane Eye Clinic joins PRISM’s network of affiliated practices.
Sydnexis Announces UK Approval of Ryjunea® by Partner Santen to Slow Progression of Childhood Myopia
DEL MAR, Calif.–(BUSINESS WIRE)–Sydnexis, Inc., (www.sydnexis.com), a biopharmaceutical company focused on pediatric progressive myopia (PPM), today noted its partner Santen’s announcement that the UK Medicines and Healthcare products Regulatory Agen…
Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that the company will host a R…
Warby Parker Announces Third Quarter 2025 Results
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (“Warby Parker” or the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the third quarter ended September 30, 2025. “This was a s…
Yunqi Capital Applauds STAAR Surgical’s Strong Third Quarter Results and Reiterates That the Proposed Sale to Alcon Should Be Terminated
HONG KONG–(BUSINESS WIRE)–Yunqi Capital Applauds STAAR Surgical’s Strong Third Quarter Results and Reiterates That the Proposed Sale to Alcon Should Be Terminated
STAAR Surgical Reports Third Quarter 2025 Results
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the third quarter ended Septe…
PolyActiva and RareSight Form Strategic Collaboration to Develop Breakthrough Treatments for Rare Pediatric Retinal Diseases
FORT WORTH, Texas & MELBOURNE, Australia & MENLO PARK, Calif.–(BUSINESS WIRE)–PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions, and RareSight, I…
LambdaVision Raises $7M Seed Round to Revolutionize Blindness Treatment Using Space-Based Manufacturing
WOODBRIDGE, Conn.–(BUSINESS WIRE)–LambdaVision, a biotech innovator leveraging microgravity to manufacture its investigational protein-based artificial retina to help patients regain sight lost to retinal degenerative diseases, has closed a $7M seed …
Tenpoint Therapeutics Ltd. Announces Submission of a New Drug Application for BRIMOCHOL™ PF for the Treatment of Presbyopia to the MFDS in South Korea
LONDON & SEATTLE & HONG KONG–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global, commercial-ready biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced that its partner, Zhaoke…
Eyexora Establishes Co-Headquarters in Singapore to Accelerate Growth Across Asia-Pacific
SINGAPORE–(BUSINESS WIRE)–Eyexora Establishes Co-Headquarters in Singapore to Accelerate Growth Across Asia-Pacific
Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today reported recent busine…
National Vision Holdings, Inc. Reports Third Quarter 2025 Financial Results
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision,” “we,” “our,” “us” or the “Company”) today reported its financial results for the third quarter ended September 27, 2025. “Our strong performance this quarter…
Broadwood Partners Condemns Alcon’s Fallacious Attacks on STAAR Surgical and Its Prospects
NEW YORK–(BUSINESS WIRE)–Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today commented on the investor presentation issued by Alcon Inc. (“Alcon”) (NYSE: ALC) regarding its proposed acquisition of STAAR Surgical Company (“STAAR” o…
Sydnexis Announces Topline Pivotal Data from Phase 3 STAR Trial of SYD-101 for Patients with Pediatric Progressive Myopia Presented at AMCP Nexus 2025
DEL MAR, Calif.–(BUSINESS WIRE)–Sydnexis Announces Topline Pivotal Data from Phase 3 STAR Trial of SYD-101 for Patients with Pediatric Progressive Myopia Presented at AMCP Nexus 2025
Alcon Releases Investor Discussion Materials Reinforcing Certain Value of Merger Proposal for STAAR Stockholders
GENEVA–(BUSINESS WIRE)–Alcon Releases Investor Discussion Materials Reinforcing Certain Value of Merger Proposal for STAAR Stockholders
Bausch + Lomb to Hold Investor Day on Nov. 13
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will hold an investor day on Thursday, Nov. 13, 2025, at the New York Stock Exchan…
Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced the successf…
Glaukos Announces Participation in Upcoming Investor Conferences
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that i…